Is Cardiff Oncology, Inc. (CRDF) a Buy, Sell, or Hold?
NASDAQ : CRDF
Cardiff Oncology, Inc. — News
$0.9919 USD
$0.03 (3.28%)
- Volume
- 633.18K
- Average Volume
- 1.51M
- Market Capitalization
- $65.09M
- P/E Ratio
- -1.48
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $3.31
- Year Low
- $0.76
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.27
| Source | Headline |
|---|---|
|
Cardiff Oncology Announces $10 Million Registered Direct Offering
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per share and accompanying warrant in a registered direct offering. In addition, certain members of the Company's officers and directors are participating in the offering and have entered into definitive agreements for the purchase and sale of an aggregate of 731,707 shares of the Company's common stock and accompanying warrants to purchase up to an aggregate of 731,707 shares of the Company's common stock, at a purchase price of $1.435 per share and accompanying warrant. globenewswire.com - 2026-07-15 08:00:00 |
|
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript seekingalpha.com - 2026-06-03 15:12:07 |
|
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - globenewswire.com - 2026-06-02 09:06:00 |
|
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026. globenewswire.com - 2026-06-01 16:01:00 |
|
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data globenewswire.com - 2026-05-21 17:00:00 |
|
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday said that it filed a lawsuit against Nerviano Medical Sciences (NMS), disputing NMS's claim that Cardiff materially breached their licensing agreement for onvansertib. benzinga.com - 2026-05-20 14:11:46 |
|
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial globenewswire.com - 2026-05-14 16:10:00 |
